Contact Us

Yes. APOD rescue experiments require attention to secreted lipocalin architecture: • Construct design: use a codon-modified APOD sequence with a small N-terminal tag (FLAG, HA, after signal peptide cleavage) or C-terminal tag carefully placed. APOD has signal peptide and mature lipocalin β-barrel domain — preserve protein integrity. • Secretion validation: confirm conditioned media APOD secretion. • Ligand-binding-deficient rescue: β-barrel cavity mutations disrupt hydrophobic ligand binding. • Functional readout: rescue should restore APOD-dependent phenotypes identified during knockout characterization. HEK293T transduces with very high efficiency and supports stable rescue line generation.

The choice depends on whether you are studying AGER (RAGE, receptor for advanced glycation end-products)'s role as a multi-ligand pattern recognition receptor or modeling its functions in diabetic complications, neurodegeneration, and airway disease. The Knockout line is the standard tool for asking whether RAGE is required for these processes — AGER/RAGE is a type I transmembrane receptor of the immunoglobulin superfamily that recognizes diverse ligands: advanced glycation end-products (AGEs, formed under hyperglycemia in diabetes), S100/calgranulin proteins, HMGB1, β-amyloid (relevant to Alzheimer's disease), DNA, RNA; RAGE engagement activates NF-κB, MAPK, and inflammatory pathways. Overexpression is useful for studying RAGE gain-of-function effects. For airway and inflammation research, the EDITGENE AGER Knockout in BEAS-2B is uniquely valuable — RAGE is one of the most highly expressed receptors in lung tissue (particularly alveolar type I cells) and is critical in COPD, idiopathic pulmonary fibrosis, asthma, and acute lung injury. RAGE has multiple splice variants including soluble RAGE (sRAGE, a decoy receptor). Rescue with wild-type, ligand-binding-deficient, or sRAGE isoform enables structure-function studies. The knockout is a critical specificity tool for ⭐⭐ azeliragon (TTP488, RAGE antagonist completing Phase III for Alzheimer's disease and diabetic complications), and emerging RAGE-targeted therapeutics in lung disease, neurodegeneration, and metabolic disease.

Yes. RAGE rescue experiments are well-established for pattern recognition receptor research: • Construct design: use a codon-modified AGER sequence with a small intracellular C-terminal tag (FLAG, HA). RAGE has extracellular V-type Ig (ligand binding), C1, C2 Ig-like domains, transmembrane span, and intracellular signaling tail (the ddRAGE tail mediates pro-inflammatory signaling) — preserve all elements. • Surface localization validation: confirm plasma membrane RAGE by cell surface staining before ligand binding studies. • Ligand-binding-deficient rescue: V-domain mutations disrupt ligand binding. • sRAGE rescue: soluble RAGE (lacking transmembrane domain, secreted) generates a decoy receptor — useful for studying sRAGE biology. • Functional readout: rescue should restore RAGE-ligand-induced NF-κB activation. BEAS-2B-specific considerations: • BEAS-2B is a SV40-immortalized normal human bronchial epithelial cell line — widely used for respiratory epithelial biology, airway inflammation, COPD, and asthma research. • Lentiviral transduction is supported but may require optimization compared to standard transformed cell lines. • BEAS-2B retains bronchial epithelial features and is highly relevant for AGER/RAGE airway disease research.

The choice depends on whether you are studying ACHE (acetylcholinesterase)'s role as the principal acetylcholine-hydrolyzing enzyme or modeling its applications in Alzheimer's disease, neuromuscular biology, and nerve agent toxicology. The Knockout line is the standard tool for asking whether ACHE is required for these processes — ACHE is the enzyme that rapidly hydrolyzes the neurotransmitter acetylcholine at cholinergic synapses and neuromuscular junctions, terminating cholinergic signaling; ACHE is the target of clinically important cholinesterase inhibitors and the principal target of organophosphate nerve agents and pesticides. Overexpression is useful for studying ACHE gain-of-function effects. For cholinergic biology research, the EDITGENE ACHE Knockout in HAP1 enables study of ACHE biology. BCHE (butyrylcholinesterase) expression analysis aids interpretation given partial functional overlap. Rescue with wild-type or catalytically-dead ACHE enables structure-function studies. The knockout is a critical specificity tool for ⭐⭐ Alzheimer's disease cholinesterase inhibitors (⭐ donepezil/Aricept, rivastigmine/Exelon, galantamine/Razadyne), myasthenia gravis treatments (pyridostigmine, neostigmine), and organophosphate/nerve agent toxicology research.

Yes. ACHE rescue experiments are well-established for cholinesterase research: • Construct design: use a codon-modified ACHE sequence with a small tag — ACHE has multiple splice variants (synaptic AChE-S/T, erythrocytic AChE-E) with different C-termini; tag placement requires care to preserve the relevant isoform. • Catalytically-dead rescue: S203A in the catalytic serine triad abolishes acetylcholinesterase activity. • Surface/secretion validation: confirm appropriate localization (GPI-anchored or secreted depending on isoform). • Functional readout: rescue should restore acetylcholine hydrolysis measured by Ellman assay. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.

The choice depends on whether you are studying APTX (aprataxin)'s role as a 5'-adenylated DNA/RNA processing enzyme or modeling ataxia with oculomotor apraxia 1 (AOA1). The Knockout line is the standard tool for asking whether APTX is required for these processes — APTX is a HIT-family enzyme that hydrolyzes 5'-adenylate (AMP-DNA/RNA) intermediates generated from abortive DNA ligase reactions; APTX removes 5'-adenylate groups blocking subsequent ligation, enabling completion of DNA single-strand break repair and base excision repair. Overexpression is useful for studying APTX gain-of-function effects. For DNA repair and neurodegeneration research, the EDITGENE APTX Knockout in HAP1 enables study of APTX biology. APTX biallelic loss-of-function mutations cause ⭐ ataxia with oculomotor apraxia type 1 (AOA1, EAOH), an autosomal recessive cerebellar ataxia with oculomotor apraxia and progressive sensory-motor neuropathy. Rescue with wild-type or catalytically-dead APTX (H260A in HIT motif) enables structure-function studies. The knockout is valuable for studying DNA strand break repair, AOA1 disease modeling, and TDP1-APTX cooperation in DNA-end processing.

Yes. APTX rescue experiments require attention to HIT family architecture: • Construct design: use a codon-modified APTX sequence with a small C-terminal tag (FLAG, HA). APTX has N-terminal FHA domain (XRCC1 binding), central HIT domain (catalytic), and C-terminal zinc finger — preserve all elements. • Catalytically-dead rescue: H260A in the HIT motif abolishes 5'-AMP-DNA hydrolysis activity. • AOA1 patient mutation rescue: V263G, W279X enable disease genotype-function studies. • Functional readout: rescue should restore 5'-adenylated DNA processing and SSB repair. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.

The choice depends on whether you are studying ACVR1B (ALK4, activin receptor type 1B)'s role as the principal type I activin receptor or modeling activin/SMAD2/3 signaling. The Knockout line is the standard tool for asking whether ALK4 is required for these processes — ACVR1B/ALK4 is a type I serine/threonine kinase receptor that, upon activin binding to type II receptors (ACVR2A/ACVR2B), is recruited and phosphorylated, then phosphorylates SMAD2/3 to transduce activin and some GDF signals; ALK4 is the principal type I receptor for activin signaling. Overexpression is useful for studying ACVR1B gain-of-function effects. For activin signaling research, the EDITGENE ACVR1B Knockout in HAP1 enables study of ALK4-specific functions. This product complements the parallel ACVR1B & TGFBR1 Double Knockout in HEK293 (also available) for systematic type I receptor dissection. Rescue with wild-type, kinase-dead, or constitutively active (T206D) ACVR1B enables structure-function studies. The knockout is valuable for studying activin-SMAD2/3 signaling and as a specificity tool for ALK4/5 inhibitors (SB-431542, galunisertib affect both ALK4 and ALK5). HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.

Yes. ACVR1B/ALK4 rescue experiments are well-established for activin receptor research: • Construct design: use a codon-modified ACVR1B sequence with a small intracellular C-terminal tag (FLAG, HA). ALK4 has extracellular ligand-binding domain, transmembrane span, GS domain, and intracellular kinase domain — preserve all elements. • Surface localization validation: confirm plasma membrane localization before functional assays. • Kinase-dead rescue: K234R mutation in the ATP-binding lysine abolishes catalytic activity. • Constitutively active rescue: T206D mutation in the GS domain generates constitutively active ALK4. • Functional readout: rescue should restore activin-induced phospho-SMAD2/3 signaling. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.

The choice depends on whether you are studying ARID1A (AT-rich interaction domain 1A, BAF250A)'s role as the principal BAF/SWI/SNF chromatin remodeling complex DNA-binding subunit or modeling ARID1A-mutated cancers for synthetic lethal therapy. The Knockout line is the standard tool for asking whether ARID1A is required for these processes — ARID1A is the principal SWI/SNF (BAF) complex DNA-binding subunit (one of ARID1A/ARID1B paralogs that are mutually exclusive in canonical BAF); ARID1A is one of the most frequently mutated tumor suppressors in cancer (~20% of all cancers, especially ovarian clear cell carcinoma, endometrial cancer, gastric cancer, hepatocellular carcinoma), typically with loss-of-function mutations. Overexpression is useful for studying ARID1A in heterologous expression contexts. For cancer biology and synthetic lethality research, the EDITGENE ARID1A Knockout in HCT 116 is uniquely valuable — HCT 116 is MSI-H colorectal cancer, providing a relevant context for ARID1A loss biology. Rescue with wild-type ARID1A is the standard specificity control. The knockout is a critical specificity tool for ⭐⭐ ARID1A-mutant synthetic lethal approaches: ⭐⭐ EZH2 inhibitors (tazemetostat, FDA-approved for epithelioid sarcoma; in clinical development for ARID1A-mutant ovarian cancer based on tazemetostat-ARID1A synthetic lethal observations), ARID1B paralog dependency (single ARID1A loss creates dependency on ARID1B in BAF complex), and emerging ARID1A-mutated cancer therapeutic strategies.

Yes, with considerations for this very large protein: • Construct design: ARID1A is a ~242 kDa BAF complex DNA-binding subunit with N-terminal ARID DNA-binding domain — full-length cDNA rescue is technically challenging due to large mRNA size. • Domain-focused rescue: ARID domain or specific regions can be used for targeted functional rescue. • BAF complex partnership: rescue interpretation considers other BAF subunits (SMARCA4/BRG1, SMARCB1, ARID1B) expression. • Cancer mutation rescue: rescue with patient-derived ARID1A mutations enables disease genotype-function studies. • Functional readout: rescue should restore BAF complex assembly and chromatin accessibility. HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying ADH5 (alcohol dehydrogenase 5, ADH3, GSNOR, glutathione-dependent formaldehyde dehydrogenase)'s role as the principal endogenous formaldehyde clearance enzyme or modeling AMeD syndrome and emerging research on endogenous aldehydes. The Knockout line is the standard tool for asking whether ADH5 is required for these processes — ADH5 is an atypical alcohol dehydrogenase that, unlike class I ADHs (ethanol-oxidizing ADH1/2/4), oxidizes formaldehyde-glutathione adducts (S-hydroxymethylglutathione → S-formylglutathione) and reduces S-nitrosoglutathione (GSNO); ADH5 has dual roles in endogenous formaldehyde clearance (formaldehyde is generated as a byproduct of multiple cellular processes including one-carbon metabolism and demethylation) and S-nitrosothiol homeostasis (GSNOR/GSNO reductase). Overexpression is useful for studying ADH5 gain-of-function effects. For endogenous aldehyde research, the EDITGENE ADH5 Knockout in HCT 116 is uniquely valuable — landmark studies (Dingler et al. Molecular Cell 2020; Mu et al. Nature 2021) identified ⭐⭐ ADH5/ALDH2 dual deficiency syndrome (AMeD, aplastic anemia/mental retardation/dwarfism) caused by biallelic ADH5 loss-of-function combined with ALDH2*2 East Asian variant; this established endogenous formaldehyde as a major DNA damage source. Rescue with wild-type ADH5 is the standard specificity control. The knockout is valuable for studying endogenous formaldehyde biology, formaldehyde-induced DNA damage, ICL repair coupling, GSNO/S-nitrosothiol signaling, and emerging GSNOR inhibitor research (S-nitroso-N-acetyl-DL-penicillamine, cavosonstat/N91115 in asthma trials).

Yes. ADH5 rescue experiments are well-established for endogenous aldehyde research: • Construct design: use a codon-modified ADH5 sequence with a small C-terminal tag (FLAG, HA). ADH5 has the canonical alcohol dehydrogenase architecture with active site zinc and NAD⁺/NADP⁺ binding — preserve all elements. • Catalytically-dead rescue: active site zinc-binding mutations abolish formaldehyde dehydrogenase activity. • AMeD syndrome mutation rescue: rescue with patient-derived ADH5 mutations (combined with ALDH2*2 background where appropriate) for disease modeling. • Functional readout: rescue should restore formaldehyde clearance and S-nitrosoglutathione reductase activity. HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation.

ACVR2A and ACVR2B are the two type II activin receptors — serine/threonine kinase receptors that bind activins, myostatin (GDF8), GDF11, BMPs, and other TGF-β superfamily ligands; upon ligand binding, the type II receptor recruits and phosphorylates type I receptors (ALK4/ACVR1B, ALK5, ALK7), which then phosphorylate SMAD2/3 (activin/myostatin branch) to regulate gene expression. ACVR2A and ACVR2B share substantial ligand and functional overlap, with myostatin/GDF11-mediated muscle growth suppression being a major shared function. This ligand-trap axis is the basis of several clinically important therapeutics. The choice between knockout and overexpression depends on whether you are studying ACVR2A in the HAP1 haploid platform for systematic genetic analysis. This ACVR2A Knockout in HAP1 enables study of ACVR2A-specific functions in a clean haploid background. Overexpression is useful for studying ACVR2A gain-of-function effects. Important consideration: ACVR2B paralog expression analysis aids interpretation given substantial functional overlap. This product complements the parallel ACVR2A Knockout in HEK293 and the ACVR2A & ACVR2B Double Knockout in HEK293 (both also available) for systematic cross-background paralog dissection. Rescue with wild-type or kinase-dead ACVR2A is the standard specificity control. The knockout is valuable for studying activin/myostatin type II receptor biology and as a specificity tool for sotatercept/luspatercept/bimagrumab-class ligand traps. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.

Yes. ACVR2A rescue in HAP1 follows the same considerations as the HEK293 product: • Construct design: same considerations as ACVR2A/HEK293 rescue (kinase domain preservation, intracellular C-terminal tag, surface localization validation). • Kinase-dead rescue: K219R mutation abolishes catalytic activity. • Cross-background validation: parallel rescue in HAP1 and HEK293 confirms ACVR2A-specific phenotypes. • Functional readout: rescue should restore activin/myostatin-induced phospho-SMAD2/3. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.